Unmet Clinical Need: Developing Prognostic Biomarkers and Precision Medicine to Forecast Early Tumor Relapse, Detect Chemo-Resistance and Improve Overall Survival in High-Risk Breast Cancer

Chemo-resistant breast cancer is a major barrier to curative treatment for a significant number of women with breast cancer. Neoadjuvant chemotherapy (NACT) is standard first- line treatment for most women diagnosed with high-risk TNBC, HER2+, and locally advanced ER+ breast cancer. Current clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Gagan, Lee, Caroline Dasom, Guye, Mary L, Van Sciver, Robert E, Lee, Michael P, Lafever, Alex C, Pang, Anthony, Tang-Tan, Angela M, Winston, Janet S, Samli, Billur, Jansen, Rick J, Hoefer, Richard A, Tang, Amy H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295150/
https://www.ncbi.nlm.nih.gov/pubmed/32542231
http://dx.doi.org/10.36959/739/525

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295150/
https://www.ncbi.nlm.nih.gov/pubmed/32542231
http://dx.doi.org/10.36959/739/525

Ejemplares similares